Author: admin

DelveInsight’s “Interstitial Lung Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Interstitial Lung Disease, historical and forecasted epidemiology as well as the Interstitial Lung Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Interstitial Lung Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Interstitial Lung Disease Market Forecast

Some of the key facts of the Interstitial Lung Disease Market Report:

• The Interstitial Lung Disease market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

• In February 2025, Boehringer Ingelheim’s lung disease treatment, nerandomilast, has achieved success in a Phase III trial, positioning the company to pursue approval for its use in a second condition. Topline results from the Phase III FIBRONEER-ILD study (NCT05321082) indicate that nerandomilast enhanced lung function in patients with progressive fibrosing interstitial lung diseases (PF-ILDs), excluding idiopathic pulmonary fibrosis (IPF). Previously, the company conducted a separate IPF trial, which contributed to its new drug application (NDA) submission last year.

• Key Interstitial Lung Disease Companies: J2H Biotech, Crystec Pharma, Apie Therapeutics, BLR Bio, ImmunoMet Therapeutics, AdAlta Limited, Genentech, Bristol-Myers Squibb, Sunshine Lake Pharma, aTyr Pharma, FibroGen, Boehringer Ingelheim, and others

• Key Interstitial Lung Disease Therapies: J2H P1905, CR405, APT-101, BLR-200, M-156, AD-214, Vixarelimab, Abatacept, HEC585, Efzofitimod, Pamrevlumab, BI-1015550, and others

• The Interstitial Lung Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Interstitial Lung Disease pipeline products will significantly revolutionize the Interstitial Lung Disease market dynamics.

Interstitial Lung Disease Overview

Interstitial lung disease (ILD) is a broad term that refers to a group of lung disorders characterized by inflammation and scarring (fibrosis) of the interstitium, which is the tissue that surrounds and supports the air sacs (alveoli) in the lungs. This inflammation and scarring can impair the ability of the lungs to function properly, leading to symptoms such as cough, shortness of breath, and decreased exercise tolerance.

Get a Free sample for the Interstitial Lung Disease Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/interstitial-lung-disease-market

Interstitial Lung Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Interstitial Lung Disease Epidemiology Segmentation:

The Interstitial Lung Disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Interstitial Lung Disease

• Prevalent Cases of Interstitial Lung Disease by severity

• Gender-specific Prevalence of Interstitial Lung Disease

• Diagnosed Cases of Episodic and Chronic Interstitial Lung Disease

Download the report to understand which factors are driving Interstitial Lung Disease epidemiology trends @ Interstitial Lung Disease Epidemiology Forecast

Interstitial Lung Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Interstitial Lung Disease market or expected to get launched during the study period. The analysis covers Interstitial Lung Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Interstitial Lung Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Interstitial Lung Disease Therapies and Key Companies

• J2H P1905: J2H Biotech

• CR405: Crystec Pharma

• APT-101: Apie Therapeutics

• BLR-200: BLR Bio

• M-156: ImmunoMet Therapeutics

• AD-214: AdAlta Limited

• Vixarelimab: Genentech

• Abatacept: Bristol-Myers Squibb

• HEC585: Sunshine Lake Pharma

• Efzofitimod: aTyr Pharma

• Pamrevlumab: FibroGen

• BI-1015550: Boehringer Ingelheim

Discover more about therapies set to grab major Interstitial Lung Disease market share @ Interstitial Lung Disease Treatment Landscape

Interstitial Lung Disease Market Drivers

• Increase in prevalence of Interstitial Lung Disease (ILD), increase in geriatric population are some of the important factors that are fueling the Interstitial Lung Disease Market.

Interstitial Lung Disease Market Barriers

• However, frequent misdiagnosis of the disease, costly and invasive diagnostic procedures and other factors are creating obstacles in the Interstitial Lung Disease Market growth.

Scope of the Interstitial Lung Disease Market Report

• Study Period: 2019–2032

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Interstitial Lung Disease Companies: J2H Biotech, Crystec Pharma, Apie Therapeutics, BLR Bio, ImmunoMet Therapeutics, AdAlta Limited, Genentech, Bristol-Myers Squibb, Sunshine Lake Pharma, aTyr Pharma, FibroGen, Boehringer Ingelheim, and others

• Key Interstitial Lung Disease Therapies: J2H P1905, CR405, APT-101, BLR-200, M-156, AD-214, Vixarelimab, Abatacept, HEC585, Efzofitimod, Pamrevlumab, BI-1015550, and others

• Interstitial Lung Disease Therapeutic Assessment: Interstitial Lung Disease current marketed and Interstitial Lung Disease emerging therapies

• Interstitial Lung Disease Market Dynamics: Interstitial Lung Disease market drivers and Interstitial Lung Disease market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Interstitial Lung Disease Unmet Needs, KOL’s views, Analyst’s views, Interstitial Lung Disease Market Access and Reimbursement

To know more about Interstitial Lung Disease companies working in the treatment market, visit @ Interstitial Lung Disease Clinical Trials and Therapeutic Assessment

Table of Contents

1. Interstitial Lung Disease Market Report Introduction

2. Executive Summary for Interstitial Lung Disease

3. SWOT analysis of Interstitial Lung Disease

4. Interstitial Lung Disease Patient Share (%) Overview at a Glance

5. Interstitial Lung Disease Market Overview at a Glance

6. Interstitial Lung Disease Disease Background and Overview

7. Interstitial Lung Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Interstitial Lung Disease

9. Interstitial Lung Disease Current Treatment and Medical Practices

10. Interstitial Lung Disease Unmet Needs

11. Interstitial Lung Disease Emerging Therapies

12. Interstitial Lung Disease Market Outlook

13. Country-Wise Interstitial Lung Disease Market Analysis (2019–2032)

14. Interstitial Lung Disease Market Access and Reimbursement of Therapies

15. Interstitial Lung Disease Market Drivers

16. Interstitial Lung Disease Market Barriers

17. Interstitial Lung Disease Appendix

18. Interstitial Lung Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Interstitial Lung Disease Market Poised for Significant Growth from 2023 to 2032, Reports DelveInsight | J2H Biotech, Crystec Pharma, Apie Therapeutics, BLR Bio, ImmunoMet Therapeutics, AdAlta

The Endocarditis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Endocarditis pipeline products will significantly revolutionize the Endocarditis market dynamics.

DelveInsight’s “Endocarditis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Endocarditis, historical and forecasted epidemiology as well as the Endocarditis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Endocarditis market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Endocarditis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Endocarditis Market Forecast

Some of the key facts of the Endocarditis Market Report:

• The Endocarditis market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

• Endocarditis is an uncommon infection in the US; over 25% of cases affect people aged 60 years or above. Yet, it is also the fourth most common life-threatening infection after sepsis, pneumonia, and intra-abdominal abscess, with an estimated inpatient mortality rate between 15 and 30%.

• According to the National Organisation for Rare Disorders (NORD, n.d.) Infective endocarditis appears to be approximately twice as common in men as women. In the past, disease onset occurred at an average age of 35.

• Key Endocarditis Companies: Lysovant, ContraFect, Basilea Pharmaceuticals, Cubist Pharmaceuticals, Basilea Pharmaceutica, Merck Sharp & Dohme, and others

• Key Endocarditis Therapies: Tonabacase (LSVT-1701), Exebacase(CF-301), ContraFect, daptomycin, Ceftobiprole medocaril, Daptomycin, and others

• The Endocarditis epidemiology based on gender analyzed that endocarditis affects males and females in a ratio of 2:1

Endocarditis Overview

Endocarditis is defined as an inflammation of the endocardial surface of the heart. This may include heart valves, mural endocardium or the endocardium that covers prosthetic valves, pacemaker/defibrillator leads, and catheters. Infective and non-infective-related causes of endocarditis must be distinguished. The inflammation is related to a bacterial or fungal infection in most cases. Approximately 80% of infective endocarditis cases are caused by the bacteria streptococci and staphylococci.

Get a Free sample for the Endocarditis Market Report:

https://www.delveinsight.com/report-store/endocarditis-market

Endocarditis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Endocarditis Epidemiology Segmentation:

The Endocarditis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Endocarditis

• Prevalent Cases of Endocarditis by severity

• Gender-specific Prevalence of Endocarditis

• Diagnosed Cases of Episodic and Chronic Endocarditis

Download the report to understand which factors are driving Endocarditis epidemiology trends @ Endocarditis Epidemiological Insights

Endocarditis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Endocarditis market or expected to get launched during the study period. The analysis covers Endocarditis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Endocarditis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Endocarditis Therapies and Key Companies

• Tonabacase (LSVT-1701): Lysovant

• Exebacase(CF-301): ContraFect

• ContraFect: Basilea Pharmaceuticals

• daptomycin: Cubist Pharmaceuticals

• Ceftobiprole medocaril: Basilea Pharmaceutica

• Daptomycin: Merck Sharp & Dohme

To know more about Endocarditis treatment, visit @ Endocarditis Medications

Scope of the Endocarditis Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Endocarditis Companies: Lysovant, ContraFect, Basilea Pharmaceuticals, Cubist Pharmaceuticals, Basilea Pharmaceutica, Merck Sharp & Dohme, and others

• Key Endocarditis Therapies: Tonabacase (LSVT-1701), Exebacase(CF-301), ContraFect, daptomycin, Ceftobiprole medocaril, Daptomycin, and others

• Endocarditis Therapeutic Assessment: Endocarditis current marketed and Endocarditis emerging therapies

• Endocarditis Market Dynamics: Endocarditis market drivers and Endocarditis market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Endocarditis Unmet Needs, KOL’s views, Analyst’s views, Endocarditis Market Access and Reimbursement

Discover more about therapies set to grab major Endocarditis market share @ Endocarditis Treatment Landscape

Table of Contents

1. Endocarditis Market Report Introduction

2. Executive Summary for Endocarditis

3. SWOT analysis of Endocarditis

4. Endocarditis Patient Share (%) Overview at a Glance

5. Endocarditis Market Overview at a Glance

6. Endocarditis Disease Background and Overview

7. Endocarditis Epidemiology and Patient Population

8. Country-Specific Patient Population of Endocarditis

9. Endocarditis Current Treatment and Medical Practices

10. Endocarditis Unmet Needs

11. Endocarditis Emerging Therapies

12. Endocarditis Market Outlook

13. Country-Wise Endocarditis Market Analysis (2020–2034)

14. Endocarditis Market Access and Reimbursement of Therapies

15. Endocarditis Market Drivers

16. Endocarditis Market Barriers

17. Endocarditis Appendix

18. Endocarditis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Endocarditis Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Lysovant, ContraFect, Basilea Pharmaceuticals

The Unstable Angina market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Unstable Angina pipeline products will significantly revolutionize the Unstable Angina market dynamics.

DelveInsight’s “Unstable Angina Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Unstable Angina, historical and forecasted epidemiology as well as the Unstable Angina market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Unstable Angina market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Unstable Angina market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Unstable Angina Market Insights

Some of the key facts of the Unstable Angina Market Report:

• The Unstable Angina market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

• In November 2024, Saghmos is developing ST-62516 (trimetazidine), a cardiorenal metabolic modulator aimed at lowering the risk of Acute Kidney Injury (AKI) and Major Adverse Cardiac and Kidney Events (MACKE) following contrast-based procedures like percutaneous coronary intervention (PCI). In the US, over one million PCI procedures are performed annually on patients with unstable angina, with around half having additional health conditions that affect PCI safety. This represents a significant unmet medical need, as no FDA-approved treatments currently exist to prevent or manage AKI and MACKE. Saghmos Therapeutics is partnering with the Duke Clinical Research Institute to refine and execute the Phase 3 trial for ST-62516.

• Coronary heart disease (CHD) impacts over 17 million adults in the United States. Of the 17 million Americans affected, 55% of those are male. Angina affects 10 million people in the United States

• According to the study of Nathan Messas, Unstable Angina or Angina pectoris is the most prevalent manifestation of myocardial ischemia and coronary artery disease (CAD), affecting up to 9 million patients in the United States

• Key Unstable Angina Companies: Tasly Pharmaceuticals, Arbor Pharmaceuticals, and others

• Key Unstable Angina Therapies: T89, AR36, and others

• The Unstable Angina epidemiology based on gender analyzed that it can be concluded that Unstable Angina is more common in males than female

Unstable Angina Overview

Unstable angina is a type of chest pain that occurs suddenly and unpredictably due to reduced blood flow to the heart. It is a medical emergency and a warning sign of an impending heart attack. Unlike stable angina, it can occur at rest, lasts longer, and may not be relieved by medication or rest. It results from the rupture of a plaque in the coronary artery, leading to partial blockage. Immediate treatment is essential to restore blood flow and prevent heart damage.

Get a Free sample for the Unstable Angina Market Report:

https://www.delveinsight.com/report-store/unstable-angina-market

Unstable Angina Market

The dynamics of the Unstable Angina market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.

“The emerging pipeline for the treatment of Unstable Angina have few candidates. These products are in mid or last stage of investigation. With the launch of emerging therapies the total market of Unstable Angina is supposed to experience immense changes in the future”

Unstable Angina Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Unstable Angina Epidemiology Segmentation:

The Unstable Angina market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Unstable Angina

• Prevalent Cases of Unstable Angina by severity

• Gender-specific Prevalence of Unstable Angina

• Diagnosed Cases of Episodic and Chronic Unstable Angina

Download the report to understand which factors are driving Unstable Angina epidemiology trends @ Unstable Angina Epidemiological Insights

Unstable Angina Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Unstable Angina market or expected to get launched during the study period. The analysis covers Unstable Angina market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Unstable Angina Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Unstable Angina Therapies and Key Companies

• T89: Tasly Pharmaceuticals

• AR36: Arbor Pharmaceuticals

To know more about Unstable Angina treatment, visit @ Unstable Angina Medications

Scope of the Unstable Angina Market Report

• Study Period: 2019–2032

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Unstable Angina Companies: Tasly Pharmaceuticals, Arbor Pharmaceuticals, and others

• Key Unstable Angina Therapies: T89, AR36, and others

• Unstable Angina Therapeutic Assessment: Unstable Angina current marketed and Unstable Angina emerging therapies

• Unstable Angina Market Dynamics: Unstable Angina market drivers and Unstable Angina market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Unstable Angina Unmet Needs, KOL’s views, Analyst’s views, Unstable Angina Market Access and Reimbursement

Discover more about therapies set to grab major Unstable Angina market share @ Unstable Angina Treatment Landscape

Table of Contents

1. Unstable Angina Market Report Introduction

2. Executive Summary for Unstable Angina

3. SWOT analysis of Unstable Angina

4. Unstable Angina Patient Share (%) Overview at a Glance

5. Unstable Angina Market Overview at a Glance

6. Unstable Angina Disease Background and Overview

7. Unstable Angina Epidemiology and Patient Population

8. Country-Specific Patient Population of Unstable Angina

9. Unstable Angina Current Treatment and Medical Practices

10. Unstable Angina Unmet Needs

11. Unstable Angina Emerging Therapies

12. Unstable Angina Market Outlook

13. Country-Wise Unstable Angina Market Analysis (2019–2032)

14. Unstable Angina Market Access and Reimbursement of Therapies

15. Unstable Angina Market Drivers

16. Unstable Angina Market Barriers

17. Unstable Angina Appendix

18. Unstable Angina Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Unstable Angina Market on Track for Major Expansion by 2032, According to DelveInsight | Tasly Pharmaceuticals, Arbor Pharmaceuticals

DelveInsight’s “Portal Hypertension Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Portal Hypertension, historical and forecasted epidemiology as well as the Portal Hypertension market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Portal Hypertension market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Portal Hypertension Market Forecast

Some of the key facts of the Portal Hypertension Market Report:

• The Portal Hypertension market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

• In May 2025, Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company specializing in innovative treatments for metabolic dysfunction-associated steatohepatitis (MASH), today reported encouraging two-year outcomes from the open-label compensated MASH cirrhosis (F4c) cohort of the Phase 3 MAESTRO-NAFLD-1 trial evaluating Rezdiffra. The 122 patients enrolled showed notable improvements from baseline in liver stiffness, liver fat content, fibrosis biomarkers, liver volume, and clinically significant portal hypertension (CSPH) risk scores.

• Around 2000 Americans per 100,000 have liver cirrhosis in the United States, and more than 90% of those who have cirrhosis go on to develop portal hypertension, according to National Institutes of Health (n.d.)

• Although it is likely similar to that of the US, the international incidence of portal hypertension is similarly unknown, with variances mostly in the underlying reasons. The major causes of portal hypertension and esophageal varices in Western countries are alcoholic and viral cirrhosis; at the time of diagnosis, gastroesophageal varices are present in 30% of patients with compensated cirrhosis and 60–70% of patients with decompensated cirrhosis

• Portal hypertension, a disease that precedes the bulk of cirrhotic patients’ deaths, eventually develops in about 90% of cirrhotic patients

• Key Portal Hypertension Companies: Boehringer Ingelheim, Galectin Therapeutics Inc., Onyx Therapeutics, Inc., Novartis, Cumberland Pharma, Conatus Pharma, Ferozsons Laboratories Ltd., Histogen, Gilead Sciences, Galectin Therapeutics Inc., and others

• Key Portal Hypertension Therapies: BI 685509, GR-MD-02, Sorafenib, Serelaxin, Ifetroban, IDN-6556, Terlipressin, Emricasan, Ambrisentan, belapectin, and others

• The Portal Hypertension epidemiology based on gender analyzed that portal hypertension affects males slightly more than females

• The Portal Hypertension market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Portal Hypertension pipeline products will significantly revolutionize the Portal Hypertension market dynamics.

Portal Hypertension Overview

A rise in the pressure inside the portal vein, which conducts blood from the digestive system to the liver, is known as portal hypertension. A obstruction in the blood flow through the liver is the root cause of the rise in pressure. Large veins (varices) grow across the oesophagus and stomach to get past the blockage as a result of increased pressure in the portal vein. The varices deteriorate and become more prone to bleeding.

Get a Free sample for the Portal Hypertension Market Report

https://www.delveinsight.com/report-store/portal-hypertension-market

Portal Hypertension Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Portal Hypertension Epidemiology Segmentation:

The Portal Hypertension market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Portal Hypertension

• Prevalent Cases of Portal Hypertension by severity

• Gender-specific Prevalence of Portal Hypertension

• Diagnosed Cases of Episodic and Chronic Portal Hypertension

Download the report to understand which factors are driving Portal Hypertension epidemiology trends @ Portal Hypertension Epidemiology Forecast

Portal Hypertension Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Portal Hypertension market or expected to get launched during the study period. The analysis covers Portal Hypertension market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Portal Hypertension Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Portal Hypertension Therapies and Key Companies

• BI 685509: Boehringer Ingelheim

• GR-MD-02: Galectin Therapeutics Inc.

• Sorafenib: Onyx Therapeutics, Inc.

• Serelaxin: Novartis

• Ifetroban: Cumberland Pharma

• IDN-6556: Conatus Pharma

• Terlipressin: Ferozsons Laboratories Ltd.

• Emricasan: Histogen

• Ambrisentan: Gilead Sciences

• belapectin: Galectin Therapeutics Inc.

Discover more about therapies set to grab major Portal Hypertension market share @ Portal Hypertension Treatment Market

Scope of the Portal Hypertension Market Report

• Study Period: 2019–2032

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Portal Hypertension Companies: Boehringer Ingelheim, Galectin Therapeutics Inc., Onyx Therapeutics, Inc., Novartis, Cumberland Pharma, Conatus Pharma, Ferozsons Laboratories Ltd., Histogen, Gilead Sciences, Galectin Therapeutics Inc., and others

• Key Portal Hypertension Therapies: BI 685509, GR-MD-02, Sorafenib, Serelaxin, Ifetroban, IDN-6556, Terlipressin, Emricasan, Ambrisentan, belapectin, and others

• Portal Hypertension Therapeutic Assessment: Portal Hypertension current marketed and Portal Hypertension emerging therapies

• Portal Hypertension Market Dynamics: Portal Hypertension market drivers and Portal Hypertension market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Portal Hypertension Unmet Needs, KOL’s views, Analyst’s views, Portal Hypertension Market Access and Reimbursement

To know more about Portal Hypertension companies working in the treatment market, visit @ Portal Hypertension Clinical Trials and Therapeutic Assessment

Table of Contents

1. Portal Hypertension Market Report Introduction

2. Executive Summary for Portal Hypertension

3. SWOT analysis of Portal Hypertension

4. Portal Hypertension Patient Share (%) Overview at a Glance

5. Portal Hypertension Market Overview at a Glance

6. Portal Hypertension Disease Background and Overview

7. Portal Hypertension Epidemiology and Patient Population

8. Country-Specific Patient Population of Portal Hypertension

9. Portal Hypertension Current Treatment and Medical Practices

10. Portal Hypertension Unmet Needs

11. Portal Hypertension Emerging Therapies

12. Portal Hypertension Market Outlook

13. Country-Wise Portal Hypertension Market Analysis (2019–2032)

14. Portal Hypertension Market Access and Reimbursement of Therapies

15. Portal Hypertension Market Drivers

16. Portal Hypertension Market Barriers

17. Portal Hypertension Appendix

18. Portal Hypertension Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Portal Hypertension Market Growth Projections 2023-2032: DelveInsight Analysis | Boehringer Ingelheim, Gilead Sciences, Novartis, Cumberland Pharma, Conatus, Onyx Therapeutics, Inc.

DelveInsight’s “Natural Killer (NK)-Cell Lymphoma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Natural Killer (NK)-Cell Lymphoma, historical and forecasted epidemiology as well as the Natural Killer (NK)-Cell Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Natural Killer (NK)-Cell Lymphoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Natural Killer (NK)-Cell Lymphoma Market Forecast

Some of the key facts of the Natural Killer (NK)-Cell Lymphoma Market Report:

• The Natural Killer (NK)-Cell Lymphoma market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

• In December 2024, Indapta Therapeutics, Inc., a private clinical-stage biotech firm focused on advanced cell therapies for cancer and autoimmune diseases, announced the closing of a $22.5 million funding round to fast-track the clinical development of its unique allogeneic Natural Killer (NK) cell therapy. The financing was led by existing investors including RA Capital Management, LP, Leaps by Bayer (Bayer AG’s impact investment arm), Vertex Ventures HC, Pontifax, and the Myeloma Investment Fund, the venture philanthropy branch of the Multiple Myeloma Research Foundation.

• In October 2024, Immunotherapy leader ImmunityBio, Inc. (NASDAQ: IBRX) announced the dosing of the first patients in an initial trial evaluating its CAR-NK cell therapy targeting CD19 for treating non-Hodgkin’s lymphoma (NHL). In the QUILT 106 study, CD19-targeted high-affinity natural killer (t-haNK) cells are initially tested as a single treatment and, after confirming safety, combined with the standard NHL therapy rituximab in patients with selected CD19+ and CD20+ relapsed/refractory B-cell NHL. This Phase 1, open-label trial plans to enroll up to 10 participants and is underway in Johannesburg, Pretoria, and Bloemfontein, South Africa.

• In October 2024, ImmunityBio announced that the first patients have been treated in an early trial investigating the potential of the company’s CAR-NK cell therapy targeting CD-19 for non-Hodgkin’s lymphoma (NHL).

• In July 2024, The U.S. Food and Drug Administration (FDA) has approved Nkarta to initiate a clinical trial evaluating its cell therapy candidate NKX019 in patients with ANCA-associated vasculitis (AAV) and other autoimmune diseases.

• The increased utilization of NK cells in addressing cancer, infections, and liver diseases significantly contributes to the expansion of the market for Natural Killer Cells therapeutics.

• Key Natural Killer (NK)-Cell Lymphoma Companies: Innate Pharma, Nektar Therapeutics, ImmunityBio, CytoVac, Celularity, and others

• Key Natural Killer (NK)-Cell Lymphoma Therapies: Monalizumab, NKTR-214 (Bempegaldesleukin), ALT 803, ALECSAT, PNK-007, and others

Natural Killer (NK)-Cell Lymphoma Overview

Natural Killer (NK)-Cell Lymphoma is a rare and aggressive type of non-Hodgkin lymphoma that arises from natural killer cells, a type of immune cell. It most commonly affects the nasal area and upper respiratory tract but can also spread to other organs. NK-cell lymphoma is often associated with the Epstein-Barr virus (EBV) and is more prevalent in Asian and Latin American populations. Symptoms may include nasal obstruction, bleeding, fever, and weight loss. Due to its aggressive nature, early diagnosis and treatment—typically involving chemotherapy and radiation—are crucial for better outcomes.

Request a sample for the Natural Killer (NK)-Cell Lymphoma Market Report:

https://www.delveinsight.com/report-store/natural-killer-nk-cell-lymphoma-market

Natural Killer (NK)-Cell Lymphoma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Epidemiology Segmentation of Natural Killer (NK)-Cell Lymphoma:

• Prevalent Cases of Natural Killer (NK)-Cell Lymphoma in the 7MM [2019-2032]

• Age-Specific Cases of Natural Killer (NK)-Cell Lymphoma in the 7MM [2019–2032]

• Gender-Specific Cases of Natural Killer (NK)-Cell Lymphoma in the 7MM [2019–2032]

• Diagnosed and Treated Cases of Natural Killer (NK)-Cell Lymphoma in the 7MM [2019–2032]

Download the report to understand which factors are driving Natural Killer (NK)-Cell Lymphoma epidemiology trends @ Natural Killer (NK)-Cell Lymphoma Epidemiology Forecast

Natural Killer (NK)-Cell Lymphoma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Natural Killer (NK)-Cell Lymphoma market or expected to get launched during the study period. The analysis covers Natural Killer (NK)-Cell Lymphoma market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Natural Killer (NK)-Cell Lymphoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Natural Killer (NK)-Cell Lymphoma Pipeline Therapies

• Monalizumab: Innate Pharma

• NKTR-214 (Bempegaldesleukin): Nektar Therapeutics

• ALT 803: ImmunityBio

• ALECSAT: CytoVac

• PNK-007: Celularity

Discover more about therapies set to grab major Natural Killer (NK)-Cell Lymphoma market share @ Natural Killer (NK)-Cell Lymphoma Medications

Scope of the Natural Killer (NK)-Cell Lymphoma Market Report

• Study Period: 2019–2032

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Natural Killer (NK)-Cell Lymphoma Companies: Innate Pharma, Nektar Therapeutics, ImmunityBio, CytoVac, Celularity, and others

• Key Natural Killer (NK)-Cell Lymphoma Therapies: Monalizumab, NKTR-214 (Bempegaldesleukin), ALT 803, ALECSAT, PNK-007, and others

• Natural Killer (NK)-Cell Lymphoma Therapeutic Assessment: Natural Killer (NK)-Cell Lymphoma current marketed and Natural Killer (NK)-Cell Lymphoma emerging therapies

• Natural Killer (NK)-Cell Lymphoma Market Dynamics: Natural Killer (NK)-Cell Lymphoma market drivers and Natural Killer (NK)-Cell Lymphoma market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Natural Killer (NK)-Cell Lymphoma Unmet Needs, KOL’s views, Analyst’s views, Natural Killer (NK)-Cell Lymphoma Market Access and Reimbursement

To know more about Natural Killer (NK)-Cell Lymphoma companies working in the treatment market, visit @ Natural Killer (NK)-Cell Lymphoma Clinical Trials and Therapeutic Assessment

Table of Contents

1. Natural Killer (NK)-Cell Lymphoma Market Report Introduction

2. Executive Summary for Natural Killer (NK)-Cell Lymphoma

3. SWOT analysis of Natural Killer (NK)-Cell Lymphoma

4. Natural Killer (NK)-Cell Lymphoma Patient Share (%) Overview at a Glance

5. Natural Killer (NK)-Cell Lymphoma Market Overview at a Glance

6. Natural Killer (NK)-Cell Lymphoma Disease Background and Overview

7. Natural Killer (NK)-Cell Lymphoma Epidemiology and Patient Population

8. Country-Specific Patient Population of Natural Killer (NK)-Cell Lymphoma

9. Natural Killer (NK)-Cell Lymphoma Current Treatment and Medical Practices

10. Natural Killer (NK)-Cell Lymphoma Unmet Needs

11. Natural Killer (NK)-Cell Lymphoma Emerging Therapies

12. Natural Killer (NK)-Cell Lymphoma Market Outlook

13. Country-Wise Natural Killer (NK)-Cell Lymphoma Market Analysis (2019–2032)

14. Natural Killer (NK)-Cell Lymphoma Market Access and Reimbursement of Therapies

15. Natural Killer (NK)-Cell Lymphoma Market drivers

16. Natural Killer (NK)-Cell Lymphoma Market barriers

17. Natural Killer (NK)-Cell Lymphoma Appendix

18. Natural Killer (NK)-Cell Lymphoma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Natural Killer (NK)-Cell Lymphoma Market to Expand Significantly by 2032, States DelveInsight Report | Innate Pharma, Nektar Therapeutics, ImmunityBio, CytoVac, Celularity

“Wilson’s Disease Treatment Market”

(Albany, USA) DelveInsight’s “Wilson’s Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Wilson’s Disease, historical and forecasted epidemiology as well as the Wilson’s Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The Wilson’s Disease market report also offers comprehensive insights into the Wilson’s Disease market size, share, Wilson’s Disease epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Wilson’s Disease market size growth forward.

To Know in detail about the Wilson’s Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Wilson’s Disease Market Forecast

Some of the key highlights from the Wilson’s Disease Market Insights Report:

• Several key pharmaceutical companies, including Orphalan, AstraZeneca, Vivet Therapeutics, Pfizer,Ultragenyx Pharmaceutical, and others, are developing novel products to improve the Wilson’s Disease treatment outlook.
• In March 2025, Eton Pharmaceuticals, Inc. announced the launch of Galzin® (zinc acetate) capsules, now available exclusively through Optime Care. Galzin is the only FDA-approved zinc therapy for Wilson disease, a rare genetic disorder causing excessive copper accumulation in the body.
• In January 2025, Eton Pharmaceuticals, Inc., announced that Galzin is an FDA-approved treatment for Wilson Disease, an ultra-rare metabolic disorder.
• According to DelveInsight’s estimates, there were approximately 8,000 diagnosed prevalent cases of Wilson’s disease across the 7MM in 2023. These cases are expected to rise during the forecast period (2024–2034).
• In 2023, the market for Wilson’s Disease was the largest in the US within the 7MM, valued at around USD 126 million, with expectations for a 13% compound annual growth rate (CAGR) over the forecast period.
• Current treatment options primarily include Chelating agents (D-penicillamine, trientine), Zinc Salts, and others. Chelating agents accounted for the largest share of the market, reaching approximately USD 123 million in 2023 for Wilson’s Disease treatment in the US.
• In May 2022, the US FDA approved Orphalan’s CUVRIOR (trientine tetrahydrochloride) for treating adults with stable Wilson’s disease who are decoupled and tolerant to penicillamine.
• The Wilson’s Disease treatment market in the 7MM is driven by factors such as increasing awareness, early diagnosis, advances in genetic testing, and ongoing research into new therapies. Rising prevalence, along with greater healthcare investments in rare diseases, further contributes to market growth. Additionally, patient advocacy efforts are helping to improve treatment options and expand the market.
• The US FDA has also granted Fast Track designation to VTX-801, a gene therapy from Vivet currently in clinical development for Wilson’s Disease. This designation is part of the FDA’s Fast Track program, aimed at expediting the development and review of innovative treatments for serious conditions with unmet medical needs.
• As per DelveInsight analysis, the Wilson’s Disease market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Wilson’s Disease Market Landscape

Wilson’s Disease Overview

According to the European Association for the Study of the Liver (EASL), Wilson’s disease is a genetic disorder characterized by impaired biliary copper excretion, leading to its accumulation, particularly in the liver and brain.

The condition is progressive, and if untreated, it can result in liver disease, central nervous system dysfunction, and even death. Early detection and treatment can help prevent severe long-term disability and life-threatening complications. Wilson’s disease typically presents with a combination of liver, neurological, and psychiatric symptoms. In children and young adults, liver disease is often the first sign, whereas individuals diagnosed later in life may not exhibit obvious liver symptoms, though mild liver disease may still be present. Symptoms of liver disease include jaundice (yellowing of the skin or eyes), fatigue, loss of appetite, and abdominal swelling. In adults, neurological or psychiatric symptoms are often the first to appear, and they are common in young adults with the condition. These symptoms may include clumsiness, tremors, difficulty walking, speech issues, cognitive impairment, depression, anxiety, and mood swings. Wilson’s disease is caused by a mutation in the ATP7B gene, which is responsible for copper transport. The disease occurs when an individual inherits the mutated gene from both parents.

Do you know the treatment paradigms for different countries? Download our Wilson’s Disease Treatment Market

Wilson’s Disease Epidemiology Insights

In 2023, there were around 37,000 prevalent cases of Wilson’s Disease across the 7MM, yet the treatment market for the condition lacks therapies specifically approved for its management. According to the analysis, the United States recorded the highest number of diagnosed prevalent cases, with approximately 2,600, followed by Japan with nearly 2,200 cases. Conversely, Spain had the fewest diagnosed prevalent cases, totaling approximately 300.

Wilson’s Disease Epidemiology Segmentation

DelveInsight’s Wilson’s Disease market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Wilson’s Disease historical patient pools and forecasted Wilson’s Disease patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Wilson’s Disease Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:

• Wilson’s Disease Prevalence
• Age-Specific Wilson’s Disease Prevalence
• Gender-Specific Wilson’s Disease Prevalence
• Diagnosed and Treatable Cases of Wilson’s Disease

Visit for more @ Wilson’s Disease Epidemiological Insights

Wilson’s Disease Market Insights:

The Wilson’s Disease market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Wilson’s Disease market trends by analyzing the impact of current Wilson’s Disease therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Wilson’s Disease market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Wilson’s Disease market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

The Wilson’s Disease market is primarily driven by increased awareness, early diagnosis, and advancements in genetic testing that enable timely intervention. A growing number of treatment options, including novel chelating agents and gene therapy research, are also accelerating market growth. Supportive regulatory frameworks and incentives for orphan drug development further boost pharmaceutical investments in Wilson’s Disease therapies. Additionally, patient advocacy groups and awareness campaigns play a crucial role in improving access to treatment and driving demand for innovative solutions.

However, the Wilson’s Disease market faces several barriers. The rarity of the disease often leads to misdiagnosis or delayed diagnosis, hindering timely treatment initiation. High treatment costs, especially for lifelong therapies, can limit access in low- and middle-income regions. Limited awareness among general practitioners and inadequate screening protocols also pose significant challenges. Furthermore, the small patient population makes large-scale clinical trials difficult, slowing down the development and commercialization of new therapies. Despite these barriers, continued research and improved diagnostic infrastructure offer hope for overcoming current limitations in the Wilson’s Disease market.

According to DelveInsight, the Wilson’s Disease market in 7MM is expected to witness a major change in the study period 2020-2034.

• In 2023, the therapeutic market for Wilson’s Disease in the 7MM was valued at approximately USD 295 million. The market is projected to grow at a CAGR of 12%, driven by increased disease awareness, improved diagnostic capabilities, and the introduction of emerging therapies.
• Among the 7MM, the United States represented the largest market share, accounting for roughly 43% of the total market in 2023. This was significantly higher compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Several new drugs are under development for Wilson’s disease, including VTX-801 by Vivet Therapeutics and UX701 by Ultragenyx Pharmaceutical. These agents aim to offer improved treatment options for this challenging condition.

Scope of the Wilson’s Disease Market Report

• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Wilson’s Disease Drugs – CUVRIOR, CUPRIOR, VTX-801, UX701, others
• Wilson’s Disease Companies – Orphalan, AstraZeneca,Vivet Therapeutics,Pfizer,Ultragenyx Pharmaceutical, and others
• Wilson’s Disease Therapeutic Assessment: Wilson’s Disease current marketed and Wilson’s Disease emerging therapies
• Wilson’s Disease Market Dynamics: Wilson’s Disease market drivers and Wilson’s Disease market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Wilson’s Disease Unmet Needs, KOL’s views, Analyst’s views, Wilson’s Disease Market Access and Reimbursement

For more information, visit Wilson’s Disease Market Analysis, Patient Pool, and Emerging Therapies

Wilson’s Disease Report Key Insights

1. Wilson’s Disease Patient Population

2. Wilson’s Disease Market Size and Trends

3. Key Cross Competition in the Wilson’s Disease Market

4. Wilson’s Disease Market Dynamics (Key Drivers and Barriers)

5. Wilson’s Disease Market Opportunities

6. Wilson’s Disease Therapeutic Approaches

7. Wilson’s Disease Pipeline Analysis

8. Wilson’s Disease Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Wilson’s Disease Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Wilson’s Disease Competitive Intelligence Analysis

4. Wilson’s Disease Market Overview at a Glance

5. Wilson’s Disease Disease Background and Overview

6. Wilson’s Disease Patient Journey

7. Wilson’s Disease Epidemiology and Patient Population

8. Wilson’s Disease Treatment Algorithm, Current Treatment, and Medical Practices

9. Wilson’s Disease Unmet Needs

10. Key Endpoints of Wilson’s Disease Treatment

11. Wilson’s Disease Marketed Products

12. Wilson’s Disease Emerging Therapies

13. Wilson’s Disease Seven Major Market Analysis

14. Attribute Analysis

15. Wilson’s Disease Market Outlook (7 major markets)

16. Wilson’s Disease Access and Reimbursement Overview

17. KOL Views on the Wilson’s Disease Market

18. Wilson’s Disease Market Drivers

19. Wilson’s Disease Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Wilson’s Disease Treatment Market 2034: EMA, PDMA, FDA Approvals, Medication, NICE Approvals, Clinical Trials, Revenue, Statistics, Therapies, Prevalence, Companies by DelveInsight

“Sickle Cell Disease Treatment Market”

(Albany, USA) DelveInsight’s “Sickle Cell Disease Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of Sickle Cell Disease, historical and forecasted epidemiology as well as the Sickle Cell Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Sickle Cell Disease market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Sickle Cell Disease market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Sickle Cell Disease treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Sickle Cell Disease market.

Request for a Free Sample Report @ Sickle Cell Disease Market Forecast

Some facts of the Sickle Cell Disease Market Report are:

• According to DelveInsight, Sickle Cell Disease market size is expected to grow at a decent CAGR by 2034.
• Leading Sickle Cell Disease companies working in the market are Cellectis, Sana Biotechnology, Global Blood Therapeutics, Inc., CSL Behring, Pfizer, Aruvant Sciences, Graphite Bio, Novartis, Agios Pharmaceuticals, Forma therapeutics, Vertex Pharmaceuticals, Global Blood Therapeutics, Inc., Alfasigma, Novo Nordisk, bluebird bio, ExCellThera, Gamida Cell, KM Biologics/Takeda, Editas Medicine, and others.
• Key Sickle Cell Disease Therapies expected to launch in the market are BPX-501 T cells, Canakinumab, EPI01, CTX001, ADAKVEO, DROXIA, ENDARI, OXBRYTA, and many others.
• In May 2025, Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company specializing in precision genetic medicines via base editing, announced it will share new findings from its BEACON Phase 1/2 clinical trial of BEAM-101 at the upcoming European Hematology Association 2025 Congress (EHA2025), scheduled for June 12–15, 2025, in Milan, Italy. BEAM-101 is an investigational ex vivo genetically modified cell therapy being developed to treat sickle cell disease (SCD), specifically in patients experiencing severe vaso-occlusive crises (VOCs).
• In November 2024, BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial-stage biopharmaceutical company focused on oncology and rare diseases, announced that an abstract featuring initial results from a Phase 1 trial of motixafortide—both as a monotherapy and in combination with natalizumab for CD34+ hematopoietic stem cell (HSC) mobilization in gene therapies for sickle cell disease (SCD)—has been accepted for oral presentation at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition, taking place December 7-10, 2024, in San Diego, California. Conducted in collaboration with Washington University School of Medicine in St. Louis, this proof-of-concept study aims to explore alternative HSC mobilization approaches to enhance the treatment experience for SCD patients undergoing gene therapy.
• In May 2024, Afimmune announced results of an Open-label Mechanistic Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Orally Administered Epeleuton in Patients With Sickle Cell Disease
• In April 2024, Pfizer announced results of an Open-label Extension Study to Evaluate the Long-term Safety of GBT021601 Administered to Participants With Sickle Cell Disease Who Have Participated in a GBT021601 Clinical Trial
• In April 2024, Novo Nordisk A/S (Forma Therapeutics, Inc.) announced results of an adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral Etavopivat, a Pyruvate Kinase Activator in Patients With Sickle Cell Disease (HIBISCUS).
• In July 2023, Novartis announced results of an Open-label, Multi-center, Phase IV, Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study.

Sickle Cell Disease Overview

Sickle cell disease (SCD) is a hereditary blood disorder characterized by the production of abnormal hemoglobin, known as hemoglobin S. This defect causes red blood cells to assume a rigid, sickle-like shape, which impedes their ability to flow smoothly through blood vessels. Consequently, these misshapen cells can obstruct blood flow, leading to severe pain, organ damage, and an increased risk of infection.

Sickle cell disease is most prevalent among individuals of African, Mediterranean, Middle Eastern, and Indian ancestry. Symptoms typically appear in early childhood and include episodes of pain (called sickle cell crises), chronic anemia, fatigue, swelling in the hands and feet, and delayed growth. Complications can be severe, including stroke, acute chest syndrome, and organ failure.

Management of Sickle cell disease involves both preventive and therapeutic strategies. Preventive measures include regular vaccinations, antibiotics to prevent infections, and hydroxyurea, a medication that reduces the frequency of pain crises and the need for blood transfusions. Pain management, blood transfusions, and bone marrow transplants are critical therapeutic options for managing acute and chronic complications.

Recent advancements in gene therapy and CRISPR technology hold promise for more effective treatments and potential cures for Sickle cell disease. Ongoing research and clinical trials aim to improve the quality of life for patients and reduce the burden of this debilitating disease.

Do you know what will be the Sickle Cell Disease market share in 7MM by 2034 @ Sickle Cell Disease Treatment Market

Sickle Cell Disease Market

The Sickle Cell Disease market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Sickle Cell Disease market trends by analyzing the impact of current Sickle Cell Disease therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Sickle Cell Disease market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Sickle Cell Disease market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Sickle Cell Disease market in 7MM is expected to witness a major change in the study period 2020-2034.

Sickle Cell Disease Epidemiology

The Sickle Cell Disease epidemiology section provides insights into the historical and current Sickle Cell Disease patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Sickle Cell Disease market report also provides the diagnosed patient pool, trends, and assumptions.

Interested to know how the emerging diagnostic approaches will be contributing in increased Sickle Cell Disease diagnosed prevalence pool? Download report @ Sickle Cell Disease Market Dynamics and Trends

Sickle Cell Disease Drugs Uptake

This section focuses on the uptake rate of the potential Sickle Cell Disease drugs recently launched in the Sickle Cell Disease market or expected to be launched in 2020-2034. The analysis covers the Sickle Cell Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Sickle Cell Disease Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Sickle Cell Disease market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Sickle Cell Disease Pipeline Development Activities

The Sickle Cell Disease report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Sickle Cell Disease key players involved in developing targeted therapeutics.

Download report to know which TOP 3 therapies will be capturing the largest Sickle Cell Disease market share by 2034? Click here @ Sickle Cell Disease Companies and Medication

Sickle Cell Disease Therapeutics Assessment

Major key companies are working proactively in the Sickle Cell Disease Therapeutics market to develop novel therapies which will drive the Sickle Cell Disease treatment markets in the upcoming years are Cellectis, Sana Biotechnology, Global Blood Therapeutics, Inc., CSL Behring, Pfizer, Aruvant Sciences, Graphite Bio, Novartis, Agios Pharmaceuticals, Forma therapeutics, Vertex Pharmaceuticals, Global Blood Therapeutics, Inc., Alfasigma, Novo Nordisk, bluebird bio, ExCellThera, Gamida Cell, KM Biologics/Takeda, Editas Medicine, and others.

Do you know how market launches of New drugs will be impacting the Sickle Cell Disease market CAGR? Download sample report @ Sickle Cell Disease Therapies and Clinical Trials

Sickle Cell Disease Report Key Insights

1. Sickle Cell Disease Patient Population

2. Sickle Cell Disease Market Size and Trends

3. Key Cross Competition in the Sickle Cell Disease Market

4. Sickle Cell Disease Market Dynamics (Key Drivers and Barriers)

5. Sickle Cell Disease Market Opportunities

6. Sickle Cell Disease Therapeutic Approaches

7. Sickle Cell Disease Pipeline Analysis

8. Sickle Cell Disease Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Sickle Cell Disease Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Sickle Cell Disease Competitive Intelligence Analysis

4. Sickle Cell Disease Market Overview at a Glance

5. Sickle Cell Disease Disease Background and Overview

6. Sickle Cell Disease Patient Journey

7. Sickle Cell Disease Epidemiology and Patient Population

8. Sickle Cell Disease Treatment Algorithm, Current Treatment, and Medical Practices

9. Sickle Cell Disease Unmet Needs

10. Key Endpoints of Sickle Cell Disease Treatment

11. Sickle Cell Disease Marketed Products

12. Sickle Cell Disease Emerging Therapies

13. Sickle Cell Disease Seven Major Market Analysis

14. Attribute Analysis

15. Sickle Cell Disease Market Outlook (7 major markets)

16. Sickle Cell Disease Access and Reimbursement Overview

17. KOL Views on the Sickle Cell Disease Market

18. Sickle Cell Disease Market Drivers

19. Sickle Cell Disease Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/ats-conference-coverage

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Sickle Cell Disease Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Prevalence, Medication, Statistics, NICE Approval.Revenue and Companies by DelveInsight

“Hereditary Angioedema Drugs Market”

(Albany, USA) DelveInsight’s “Hereditary Angioedema Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Hereditary Angioedema, historical and forecasted epidemiology as well as the Hereditary Angioedema market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The Hereditary Angioedema market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Hereditary Angioedema market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Hereditary Angioedema treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Hereditary Angioedema market.

To Know in detail about the Hereditary Angioedema market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hereditary Angioedema Market Forecast

Some of the key facts of the Hereditary Angioedema Market Report:

• The Hereditary Angioedema market size was valued ~USD 3000 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In March 2025, KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that it has completed enrollment for the open-label KONFIDENT-KID clinical trial, which is evaluating sebetralstat, a novel oral plasma kallikrein inhibitor, in pediatric patients aged 2 to 11 with hereditary angioedema (HAE).
• In February 2025, Astria Therapeutics initiated the randomized, placebo-controlled ALPHA-ORBIT Phase III trial to evaluate navenibart for treating patients with hereditary angioedema (HAE). This global, double-blind study aims to assess the safety and effectiveness of the treatment over a six-month period. The trial will involve up to 135 adults and ten adolescents with HAE type 1 or type 2. Adult participants will receive one of three dosing regimens of the therapy or a placebo across different treatment groups.
• In January 2025, Intellia Therapeutics administered the first dose to a participant in a randomized, placebo-controlled global Phase III trial of its experimental CRISPR-based treatment, NTLA-2002, for hereditary angioedema (HAE). The HAELO study is a double-blind trial designed to evaluate the safety and effectiveness of the therapy in 60 adult patients with Type I or Type II HAE.
• In December 2024, Astria Therapeutics, Inc. (NASDAQ: ATXS), a biopharmaceutical company dedicated to developing transformative treatments for allergic and immunologic conditions, today reported positive final outcomes from the target enrollment group of 16 patients in the ALPHA-STAR Phase 1b/2 clinical trial assessing navenibart (STAR-0215), a monoclonal antibody plasma kallikrein inhibitor, in hereditary angioedema (HAE) patients. The final data showed a 90-95% reduction in the average monthly attack rate at 6 months, a favorable safety and tolerability profile, and supported dosing every three months (Q3M) and every six months (Q6M). These findings highlight navenibart’s potential to become a leading therapy for HAE. Astria plans to advance navenibart into Phase 3 development, with trial initiation anticipated in Q1 2025.
• In November 2024, Ionis Pharmaceuticals, Inc. announced that the U.S. FDA has accepted the New Drug Application (NDA) for donidalorsen, an experimental RNA-targeted therapy designed to prevent hereditary angioedema (HAE) attacks in adults and pediatric patients aged 12 and older.
• In August 2024, Astria Therapeutics announced that it has chosen Ypsomed as its partner to collaborate on the development of an autoinjector for STAR-0215.
• In June 2024, KalVista has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the review of sebetralstat, an innovative oral plasma kallikrein inhibitor for treating HAE attacks in adults and pediatric patients aged 12 and older.
• In May 2024, Ionis Pharmaceuticals announced favorable outcomes from the Phase III OASIS-HAE and OASISplus studies of donidalorsen for hereditary angioedema (HAE). The studies demonstrated substantial and lasting reductions in monthly HAE attack rates, with more than 90% improvement after one year of treatment, regardless of whether the drug was administered monthly or bi-monthly. The results will be shared at the 2024 European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress in Valencia and published in The New England Journal of Medicine.
• The United States holds the largest market size for Hereditary Angioedema, estimated at around USD 2,000 million in 2023, with expectations for growth during the forecast period.
• Among the EU4 and the UK, France has the largest Hereditary Angioedema market size, approximately USD 100 million in 2023.
• Hereditary angioedema (HAE) is commonly believed to affect women more than men, with around 65% of cases occurring in females.
• Currently, three categories of Hereditary Angioedema medications-C1-INHs, 17 alpha-alkylated androgens, and antifibrinolytics-are utilized for the long-term prevention of HAE type 1 and 2.
• The diagnosed prevalent population of HAE in the United States was estimated to be approximately 7,000 cases in 2023.
• Type I Hereditary Angioedema (HAE) represented the largest share of diagnosed cases in the US, with approximately 5,500 cases in 2023.
• Analysts estimated that approximately 1,000 cases were diagnosed in the age group of 17 to under 65 years in 2023.
• Key Hereditary Angioedema Companies: Ionis Pharmaceuticals, Astria Therapeutics, KalVista Pharmaceuticals, Intellia Therapeutics, BioMarin Pharmaceutical, CSL Behring, Ionis Pharmaceuticals, Astria Therapeutics, Pharvaris Netherlands B.V, Intellia Therapeutics, Takeda, CSL Behring, Shire, and others
• Key Hereditary Angioedema Therapies: Donidalorsen (IONIS-PKK-LRx), Navenibart (STAR-0215), KVD900, NTLA-2002, BMN 331, Garadacimab, Donidalorse, STAR-0215, PHA121, NTLA-2002, TAK-743, KVD900, CSL312, Lanadelumab, and others
• The Hereditary Angioedema epidemiology based on gender analyzed that the diagnosed prevalent cases of Hereditary Angioedema in the 7MM varied according to gender, with prevalent cases higher in females than males
• The Hereditary Angioedema market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hereditary Angioedema pipeline products will significantly revolutionize the Hereditary Angioedema market dynamics.

Hereditary Angioedema Overview

Hereditary Angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodes of severe swelling in various parts of the body, including the limbs, face, intestinal tract, and airway. Hereditary Angioedema symptoms usually appear in childhood or adolescence and can worsen over time. Hereditary Angioedema is often caused by a deficiency or dysfunction of the C1-inhibitor protein, leading to uncontrolled activation of the complement system and increased vascular permeability.

Hereditary Angioedema diagnosis is typically confirmed through blood tests that measure C1-inhibitor levels and function. Hereditary Angioedema can often be misdiagnosed as allergic reactions or gastrointestinal conditions, leading to delayed treatment. Hereditary Angioedema treatment options include on-demand therapies for acute attacks and long-term prophylactic therapies to prevent future episodes. Hereditary Angioedema management also involves patient education and avoidance of known triggers such as stress, trauma, or certain medications.

Hereditary Angioedema types include Type I (low C1-inhibitor levels), Type II (non-functional C1-inhibitor), and HAE with normal C1-inhibitor levels. Hereditary Angioedema awareness is critical to improving diagnosis rates and treatment outcomes. Hereditary Angioedema research is advancing rapidly, offering hope for better therapies and improved quality of life for patients. Hereditary Angioedema support from healthcare providers and patient communities is essential for effective disease management.

Get a Free sample for the Hereditary Angioedema Market Report: Hereditary Angioedema Treatment Market

Hereditary Angioedema Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Hereditary Angioedema Epidemiology Segmentation:

The Hereditary Angioedema market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

• Total Prevalence of Hereditary Angioedema
• Prevalent Cases of Hereditary Angioedema by severity
• Gender-specific Prevalence of Hereditary Angioedema
• Diagnosed Cases of Episodic and Chronic Hereditary Angioedema

Download the report to understand which factors are driving Hereditary Angioedema epidemiology trends @ Hereditary Angioedema Epidemiology Forecast

Hereditary Angioedema Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hereditary Angioedema market or expected to get launched during the study period. The analysis covers Hereditary Angioedema market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Hereditary Angioedema Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Hereditary Angioedema Therapies and Key Companies

• Donidalorsen (IONIS-PKK-LRx): Ionis Pharmaceuticals
• Navenibart (STAR-0215): Astria Therapeutics
• KVD900: KalVista Pharmaceuticals
• NTLA-2002: Intellia Therapeutics
• BMN 331: BioMarin Pharmaceutical
• Garadacimab: CSL Behring
• Donidalorse: Ionis Pharmaceuticals
• STAR-0215: Astria Therapeutics
• PHA121: Pharvaris Netherlands B.V
• NTLA-2002: Intellia Therapeutics
• TAK-743: Takeda
• KVD900: KalVista Pharmaceuticals
• CSL312: CSL Behring
• Lanadelumab: Shire

Discover more about therapies set to grab major Hereditary Angioedema market share @ Hereditary Angioedema Medication and Companies

Hereditary Angioedema Market Strengths

• Increasing identification of a novel genetic mutation in various regions warranting further focus on the types and associated pathophysiology, including recognition of hormonal changes

Hereditary Angioedema Market Opportunities

• Proliferating demand for therapies with improved patient compliance, fewer side effects, improved resistance profile, and long-acting therapies

Scope of the Hereditary Angioedema Market Report

• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Hereditary Angioedema Companies: Ionis Pharmaceuticals, Astria Therapeutics, KalVista Pharmaceuticals, Intellia Therapeutics, BioMarin Pharmaceutical, CSL Behring, Ionis Pharmaceuticals, Astria Therapeutics, Pharvaris Netherlands B.V, Intellia Therapeutics, Takeda, CSL Behring, Shire, and others
• Key Hereditary Angioedema Therapies: Donidalorsen (IONIS-PKK-LRx), Navenibart (STAR-0215), KVD900, NTLA-2002, BMN 331, Garadacimab, Donidalorse, STAR-0215, PHA121, NTLA-2002, TAK-743, KVD900, CSL312, Lanadelumab, and others
• Hereditary Angioedema Therapeutic Assessment: Hereditary Angioedema current marketed and Hereditary Angioedema emerging therapies
• Hereditary Angioedema Market Dynamics: Hereditary Angioedema market drivers and Hereditary Angioedema market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Hereditary Angioedema Unmet Needs, KOL’s views, Analyst’s views, Hereditary Angioedema Market Access and Reimbursement

To know more about Hereditary Angioedema companies working in the treatment market, visit @ Hereditary Angioedema Clinical Trials and Therapeutic Assessment

Table of Contents

1. Hereditary Angioedema Market Report Introduction

2. Executive Summary for Hereditary Angioedema

3. SWOT analysis of Hereditary Angioedema

4. Hereditary Angioedema Patient Share (%) Overview at a Glance

5. Hereditary Angioedema Market Overview at a Glance

6. Hereditary Angioedema Disease Background and Overview

7. Hereditary Angioedema Epidemiology and Patient Population

8. Country-Specific Patient Population of Hereditary Angioedema

9. Hereditary Angioedema Current Treatment and Medical Practices

10. Hereditary Angioedema Unmet Needs

11. Hereditary Angioedema Emerging Therapies

12. Hereditary Angioedema Market Outlook

13. Country-Wise Hereditary Angioedema Market Analysis (2020-2034)

14. Hereditary Angioedema Market Access and Reimbursement of Therapies

15. Hereditary Angioedema Market Drivers

16. Hereditary Angioedema Market Barriers

17. Hereditary Angioedema Appendix

18. Hereditary Angioedema Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hereditary Angioedema Drugs Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Prevalence, Medication, Statistics, NICE Approval.Revenue and Companies by DelveInsight